Savings Cards and Copay Programmes
Who is eligible and who is excluded.
Released: · Last reviewed:
Lilly’s Zepbound savings card is for people with commercial insurance: it can lower the copay for up to 11 fills a calendar year, and its current terms end December 31, 2026. People on Medicare, Medicaid or other government plans are excluded; self-pay prices through LillyDirect are the fallback.
What the main programs offer
- Lilly Zepbound savings card: commercial insurance only; up to 11 fills a calendar year; current terms end December 31, 2026.
- LillyDirect self-pay: Zepbound vials at $299 (2.5 mg), $399 (5 mg) and $449 (7.5 to 15 mg with each refill within 45 days; otherwise $499 at 7.5 mg and $699 at 10 to 15 mg).
- NovoCare self-pay (Wegovy): $349 a month for pens, with $199 for two fills of the 0.25 and 0.5 mg doses for new patients through December 31, 2026; Wegovy HD 7.2 mg $399; Wegovy pill $149 to $299 by dose.
- Medicare: manufacturer savings cards exclude government plans; the GLP-1 Bridge ($50 copay) is the Medicare route for those who qualify.
Compounded tirzepatide is cash-pay only; no savings card applies to it.
All-in monthly cost = medication plus any mandatory recurring fee, at a named dose, month to month, before tax and before prepaid discounts. Competitor prices read October 15, 2026; NexLife’s as of November 6, 2026. How we verify a price.
Where this sits in the decision
Brand and compounded are different products under different regulatory regimes at very different prices. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. Brand product is reviewed, metered and traceable, and costs more. Both are legitimate choices; only one of them is often described as the other.
What the price difference actually buys
Pre-market review of that specific product, standardised metered dosing in a device, a manufacturer quality system and full supply-chain traceability. Whether that is worth the annual difference is a personal judgement, and anyone telling you the two are simply equivalent is glossing a real distinction.
Coverage changes the answer
Insurance covers indications rather than molecules, and compounded preparations are effectively a cash market. A covered brand prescription at a modest copay beats every compounded route; an uncovered brand prescription rarely does. Establish which you face before comparing prices.
Why this distinction changes what you pay
Every structural difference in this market resolves into money at a maintenance dose. Whether a programme charges a membership, whether it reprices with the dose, whether it demands a term, and whether it bundles or splits its charges together account for most of the gap between the lowest and highest all-in prices we track.
None of those differences is visible in an advertised headline figure, which is the reason this site exists in the form it does.
How to act on it this week
Price the dose you expect to maintain on rather than the starter dose. Add every recurring fee. Ask whether the quoted rate holds at renewal. Establish who compounds the medicine. And do not enter a prepaid term until you have held a maintenance dose for a cycle.
Those five steps take under an hour and reliably beat any amount of comparison reading, because they surface the information that comparison tables omit.
How this connects to what you will actually pay
Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 15 programs we can price at 10 mg, that runs from $129 to $399 a month all-in, about three times as much at the top as at the bottom, for compounded tirzepatide from the same category of licensed pharmacy.
One of those 15 programs charges a recurring program fee on top of medication, and 10 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.
What we could verify and what we could not
15 of the 32 programs we track have a month-to-month 10 mg price we read on the program’s own site (October 15, 2026; NexLife as of November 6, 2026). The rest print no comparable price, blocked our reader or sell brand Zepbound only, and we show no third-party figure for them. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.
Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.
The regulatory distinction that sits under all of this
Compounded tirzepatide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. Compounded tirzepatide is made with the drug in Zepbound but is not the same product, and FDA does not review it before sale; the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.
That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.
Two products, two regimes, two prices
Brand tirzepatide is FDA-approved, metered, traceable and priced accordingly. Compounded tirzepatide is not FDA-approved and is not reviewed for safety, effectiveness or quality before marketing; it costs less, currently from $129 a month all-in at 10 mg among the programs we track.
Both are legitimate choices. Only one of them is routinely described as the other, and that description is what regulators have acted on.
Coverage decides more of this than price does
Insurance covers indications rather than molecules, and compounded preparations are effectively a cash market. A covered brand prescription at a modest copay beats every cash route here; an uncovered one rarely does.
Establish which you face before comparing prices, because the answer changes the entire calculation rather than shifting it slightly.
What changed during 2026
Manufacturer self-pay pricing fell, a metered pen reached self-pay and retail pickup, and a flat public co-pay arrived for eligible Medicare beneficiaries. The gap the compounded market relied on narrowed from the top.
Comparisons anchored on list price — which is most of them — now overstate the compounded advantage by a wide margin.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.